Collection 1 (Apr 2017 - Aug 2021) Articles

Articles
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
StephenJ Nicholls, A Michael Lincoff, Harold E Bays, et al.
Journal:
Am Heart J 2021 May;235:104-112

First published: May 1, 2021 DOI: 10.1016/j.ahj.2020.10.060
View
- Share
Articles
Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab
Nihar R. Desai, Rolin L. Wade, Pin Xiang, et al.
Journal:
Clin Cardiol 2021; 44: 715– 722

First published: March 24, 2021 DOI: 10.1002/clc.23600
View
- Share
Articles
Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study
Anne Langsted, Børge G Nordestgaard, Pia R Kamstrup
Journal:
European Heart Journal, Volume 42, Issue 12, 21 March 2021, Pages 1147–1156

First published: March 21, 2021 DOI: doi.org/10.1093/eurheartj/ehaa1085
View
- Share
Articles
Per- and polyfluoroalkyl substances and calcifications of the coronary and aortic arteries in adults with prediabetes: Results from the diabetes prevention program outcomes study
Osorio-Yáñez C, Sanchez-Guerra M, Cardenas A, et al.
Journal:
Environ Int

First published: February 22, 2021 DOI: 10.1016/j.envint.2021.106446
View
- Share
Articles
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study
Jessica Schubert, Bertil Lindahl, Håkan Melhus, et al.
Journal:
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 243–252

First published: January 14, 2021 DOI: 10.1093/eurheartj/ehaa1011
View
- Share
Articles
Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (ADA)
Journal:
Diabetes Care 2021 Jan; 44(Supplement 1): S125-S150

First published: January 1, 2021 DOI: 10.2337/dc21-S010
View
- Share
Articles
The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction
Carl E Orringer, Michael J Blaha, Ron Blankstein, et al.
Journal:
J Clin Lipidol

First published: December 11, 2020 DOI: 10.1016/j.jacl.2020.12.005
View
- Share
Articles
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary
Yehuda Handelsman, Paul S. Jellinger, Chris K. Guerin, et al.
Journal:
Endocr Pract 2020 Oct;26(10):1196-1224

First published: October 1, 2020 DOI: https://doi.org/10.4158/CS-2020-0490
View
- Share
Articles
Genetic Testing in Dyslipidemia. A Scientific Statement from the National Lipid Association
Emily E Brown , Amy C Sturm , Marina Cuchel, et al.
Journal:
J Clin Lipidol

First published: May 6, 2020 DOI: 10.1016/j.jacl.2020.04.011
View
- Share
Articles
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach, Colin Baigent, Alberico L Catapano, et al.
Journal:
European Heart Journal, Volume 41, Issue 1, 1 January 2020, Pages 111–188

First published: August 31, 2019 DOI: 10.1093/eurheartj/ehz455
View
- Share
Articles
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy, Neil J. Stone, Alison L. Bailey, et al.
Journal:
Circulation. 2019;139:e1082–e1143

First published: November 10, 2018 DOI: 10.1161/CIR.0000000000000625
View
- Share
Articles
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
Cannon CP, Khan I, Klimchak AC, et al.
Journal:
JAMA Cardiol

First published: August 2, 2017 DOI: 10.1001/jamacardio.2017.2289
View
- Share

1 2 3

Collection 1 (Apr 2017 - Aug 2021) Articles

Articles

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

StephenJ Nicholls, A Michael Lincoff, Harold E Bays, et al.

Articles

Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab

Nihar R. Desai, Rolin L. Wade, Pin Xiang, et al.

Articles

Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study

Anne Langsted, Børge G Nordestgaard, Pia R Kamstrup

Articles

Per- and polyfluoroalkyl substances and calcifications of the coronary and aortic arteries in adults with prediabetes: Results from the diabetes prevention program outcomes study

Osorio-Yáñez C, Sanchez-Guerra M, Cardenas A, et al.

Articles

Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study

Jessica Schubert, Bertil Lindahl, Håkan Melhus, et al.

Articles

Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021

American Diabetes Association (ADA)

Articles

The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction

Carl E Orringer, Michael J Blaha, Ron Blankstein, et al.

Articles

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary

Yehuda Handelsman, Paul S. Jellinger, Chris K. Guerin, et al.

Articles

Genetic Testing in Dyslipidemia. A Scientific Statement from the National Lipid Association

Emily E Brown , Amy C Sturm , Marina Cuchel, et al.

Articles

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, Colin Baigent, Alberico L Catapano, et al.

Articles

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Scott M. Grundy, Neil J. Stone, Alison L. Bailey, et al.

Articles

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

Cannon CP, Khan I, Klimchak AC, et al.

Articles

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

StephenJ Nicholls, A Michael Lincoff, Harold E Bays, et al.

Share

Articles

Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab

Nihar R. Desai, Rolin L. Wade, Pin Xiang, et al.

Share

Articles

Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study

Anne Langsted, Børge G Nordestgaard, Pia R Kamstrup

Share

Articles

Per- and polyfluoroalkyl substances and calcifications of the coronary and aortic arteries in adults with prediabetes: Results from the diabetes prevention program outcomes study

Osorio-Yáñez C, Sanchez-Guerra M, Cardenas A, et al.

Share

Articles

Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study

Jessica Schubert, Bertil Lindahl, Håkan Melhus, et al.

Share

Articles

Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021

American Diabetes Association (ADA)

Share

Articles

The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction

Carl E Orringer, Michael J Blaha, Ron Blankstein, et al.

Share

Articles

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary

Yehuda Handelsman, Paul S. Jellinger, Chris K. Guerin, et al.

Share

Articles

Genetic Testing in Dyslipidemia. A Scientific Statement from the National Lipid Association

Emily E Brown , Amy C Sturm , Marina Cuchel, et al.

Share

Articles

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, Colin Baigent, Alberico L Catapano, et al.

Share

Articles

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Scott M. Grundy, Neil J. Stone, Alison L. Bailey, et al.

Share

Articles

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

Cannon CP, Khan I, Klimchak AC, et al.

Share